Tandem Diabetes Care Stock Current Asset
| TNDM Stock | USD 30.81 0.07 0.23% |
Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.
As of the 25th of November 2024, Non Current Assets Total is likely to grow to about 214.9 M. Also, Other Current Assets is likely to grow to about 17.4 M. Tandem | Current Asset |
Tandem Diabetes Care Company Current Asset Analysis
Tandem Diabetes' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Tandem Diabetes Current Asset | 106.98 M |
Most of Tandem Diabetes' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tandem Diabetes Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tandem Current Asset Historical Pattern
Today, most investors in Tandem Diabetes Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tandem Diabetes' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Tandem Diabetes current asset as a starting point in their analysis.
Tandem Diabetes Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Tandem Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Tandem Diabetes Care has a Current Asset of 106.98 M. This is 95.03% lower than that of the Health Care Equipment & Supplies sector and 94.65% lower than that of the Health Care industry. The current asset for all United States stocks is 98.85% higher than that of the company.
Tandem Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tandem Diabetes' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics of similar companies.Tandem Diabetes is currently under evaluation in current asset category among its peers.
Tandem Diabetes ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tandem Diabetes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tandem Diabetes' managers, analysts, and investors.Environmental | Governance | Social |
Tandem Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.0969 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 2.03 B | ||||
| Shares Outstanding | 65.68 M | ||||
| Shares Owned By Insiders | 0.76 % | ||||
| Shares Owned By Institutions | 99.24 % | ||||
| Number Of Shares Shorted | 8.39 M | ||||
| Price To Earning | 494.25 X | ||||
| Price To Book | 8.51 X | ||||
| Price To Sales | 2.37 X | ||||
| Revenue | 747.72 M | ||||
| Gross Profit | 412.99 M | ||||
| EBITDA | (194.66 M) | ||||
| Net Income | (222.61 M) | ||||
| Cash And Equivalents | 608.73 M | ||||
| Cash Per Share | 9.47 X | ||||
| Total Debt | 415.67 M | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 4.80 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (31.81 M) | ||||
| Short Ratio | 6.85 X | ||||
| Earnings Per Share | (1.94) X | ||||
| Target Price | 51.3 | ||||
| Number Of Employees | 2.4 K | ||||
| Beta | 1.37 | ||||
| Market Capitalization | 2.02 B | ||||
| Total Asset | 952.66 M | ||||
| Retained Earnings | (951.8 M) | ||||
| Working Capital | 552.73 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 26.52 M | ||||
| Net Asset | 952.66 M |
About Tandem Diabetes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tandem Diabetes Piotroski F Score and Tandem Diabetes Altman Z Score analysis. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.